All News
2020 Rheumatology Year in Review
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Read Article
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis
Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine.
Read Article
ACR 2020 Reproductive Guidelines - Lactation Guidance (Best of 2020)
In this third excerpt from the ACR guidelines on managing reproductive health issues in rheumatic disease patients, we present recommendations regarding the use of glucocorticoids and guidance on lactation and medication use post-partum.
Read Article
ACR20 - Autoinflammatory & Still's Disease Panel
This podcast features a discussion of autoinflammatory and Still's disease abstracts from virtual ACR 2020. Dr. Jack Cush is joined by a panel of experts including Drs. Olga Petryna, Bella Metha and Michael Ombrello.
Read Article
Undifferentiated Autoinflammatory Syndrome Called VEXAS
Saturday's session on autoinflammatory syndromes featured Dr. Dan Kastner addressing - The Adult with Undifferentiated Autoinflammatory Disease.
Read Article
The folly of dietary restriction in contemporary gout?
Gout has historically been considered a disease of the financially rich, rich in diet, and rich in alcohol.
Read Article
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Autoinflammatory & Still's Disease Panel #acr20 Dr. Jack Cush leads a panel of experts regarding Still's Disease and ACR 2020. https://t.co/4GmM56l1cb https://t.co/WbXMUtz6Up
Links:
#BestACR20Tweets RT @KDAO2011 : #FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Peter Nash drpnash ( View Tweet)
Links:
Links:
#BestACR20Tweets RT @KDAO2011 : FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. Olga Petryna ( @DrPetryna) recaps diagnostic tools in autoinflammatory syndromes as discussed at #ACR20. Read more via the link below. https://t.co/f3xztYzGo1 https://t.co/l9rE964nyp
Links:
